JP2023540558A5 - - Google Patents

Info

Publication number
JP2023540558A5
JP2023540558A5 JP2023515088A JP2023515088A JP2023540558A5 JP 2023540558 A5 JP2023540558 A5 JP 2023540558A5 JP 2023515088 A JP2023515088 A JP 2023515088A JP 2023515088 A JP2023515088 A JP 2023515088A JP 2023540558 A5 JP2023540558 A5 JP 2023540558A5
Authority
JP
Japan
Prior art keywords
alkyl
group
independently selected
ring
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023515088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540558A (ja
JP7821785B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/116684 external-priority patent/WO2022048665A1/en
Publication of JP2023540558A publication Critical patent/JP2023540558A/ja
Publication of JP2023540558A5 publication Critical patent/JP2023540558A5/ja
Application granted granted Critical
Publication of JP7821785B2 publication Critical patent/JP7821785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023515088A 2020-09-07 2021-09-06 ヘテロ環glp-1アゴニスト Active JP7821785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020113758 2020-09-07
CNPCT/CN2020/113758 2020-09-07
PCT/CN2021/116684 WO2022048665A1 (en) 2020-09-07 2021-09-06 Heterocyclic glp-1 agonists

Publications (3)

Publication Number Publication Date
JP2023540558A JP2023540558A (ja) 2023-09-25
JP2023540558A5 true JP2023540558A5 (cg-RX-API-DMAC10.html) 2024-09-12
JP7821785B2 JP7821785B2 (ja) 2026-02-27

Family

ID=80491636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515088A Active JP7821785B2 (ja) 2020-09-07 2021-09-06 ヘテロ環glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20230322771A1 (cg-RX-API-DMAC10.html)
EP (1) EP4211133A4 (cg-RX-API-DMAC10.html)
JP (1) JP7821785B2 (cg-RX-API-DMAC10.html)
CN (1) CN116615430A (cg-RX-API-DMAC10.html)
WO (1) WO2022048665A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JP2025510741A (ja) * 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
US20260217707A1 (en) * 2023-01-17 2026-07-30 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
KR20250168210A (ko) * 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN119630663B (zh) * 2023-06-29 2025-10-21 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
TW202506108A (zh) * 2023-06-30 2025-02-16 大陸商正大天晴藥業集團股份有限公司 含多稠環結構的化合物
AU2024317579A1 (en) * 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
EP4771001A1 (en) * 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025097835A1 (zh) * 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
AU2024394361A1 (en) * 2023-12-05 2026-06-18 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2026086876A1 (zh) * 2024-10-23 2026-04-30 郑州同源康医药有限公司 作为glp-1r激动剂的化合物
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use
CN119176808B (zh) * 2024-11-25 2025-12-26 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用
WO2026145540A1 (zh) * 2024-12-31 2026-07-09 正大天晴药业集团股份有限公司 含多稠环结构的化合物的结晶及其制备方法
WO2026158226A1 (zh) * 2025-01-21 2026-07-30 歌礼制药(中国)有限公司 一种glp-1r激动剂的注射剂及其制备方法
WO2026158232A1 (zh) * 2025-01-21 2026-07-30 歌礼制药(中国)有限公司 一种包含glp-1r激动剂的药物组合物及其制备方法
WO2026158353A1 (zh) * 2025-01-23 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927214B1 (en) * 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Similar Documents

Publication Publication Date Title
JP2023540609A5 (cg-RX-API-DMAC10.html)
JP2023513272A5 (cg-RX-API-DMAC10.html)
JP2023538949A5 (cg-RX-API-DMAC10.html)
JP2023524493A5 (cg-RX-API-DMAC10.html)
JP2023537501A5 (cg-RX-API-DMAC10.html)
JP2023546055A5 (cg-RX-API-DMAC10.html)
JP2023515404A5 (cg-RX-API-DMAC10.html)
JP2025509281A5 (cg-RX-API-DMAC10.html)
JP2023546054A5 (cg-RX-API-DMAC10.html)
WO2022031994A1 (en) Glp-1r agonists and uses thereof
KR102939810B1 (ko) 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민
TWI222971B (en) Antagonists of MCP-1 function and methods of use thereof
JP2025510741A5 (cg-RX-API-DMAC10.html)
CA3176569A1 (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
JP2024514010A5 (cg-RX-API-DMAC10.html)
JP2004503531A (ja) 2−シアノピロリジン誘導体および薬剤としてのそれらの使用
EP1396493A1 (en) Heterocyclic compounds
JP2025506474A5 (cg-RX-API-DMAC10.html)
JP2026504883A (ja) Glp-1rアゴニスト及びその使用
CN111148731A (zh) 氟苯基β-羟乙胺及其在治疗高糖血症中的用途
CN111164072A (zh) β-羟基杂环胺及其在治疗高糖血症中的用途
KR20210141622A (ko) 과혈당증의 치료에 유용한 헤테로시클릴(페닐)메탄올 화합물
JP2025512995A5 (cg-RX-API-DMAC10.html)
KR20220002903A (ko) 과혈당증의 치료에 유용한 헤테로아릴(헤테로시클릴)메탄올 화합물
US7081473B2 (en) Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient